Clinical trial
Study of Rituximab to Treat Chronic Renal Transplant Rejection
NCT00476164 · King's College London, Other · Completed
Key facts
| NCT number | NCT00476164 |
|---|---|
| Title | Study of Rituximab to Treat Chronic Renal Transplant Rejection |
| Official title | Randomised Trial of Anti-Cd20 in C4d+ Chronic Allograft Nephropathy |
| Acronym | RituxiCAN-C4 |
| Lead sponsor | King's College London, Other |
| Collaborators | Medical Research Council Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Transplantation, Graft Rejection, Immunosuppression |
| Intervention type | Drug, Other |
| Interventions | Rituximab, Control arm |
| Enrollment | 62 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2015 |
| Completion | Apr 1, 2017 |
| First posted | May 21, 2007 |
| Last update posted | Mar 5, 2020 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: